Articles tagged with Cervical Cancer
Two studies estimate the cost of delivering HPV vaccines to girls in Tanzania, finding costs substantially higher than existing infant immunization schedules. However, integration with existing health systems may improve affordability and effectiveness of HPV vaccination programs, especially in low- and middle-income countries.
A new test has been found to be more effective and cheaper than traditional cytology testing for women following pre-cervical cancer treatment. The study suggests that using HPV testing as a 'test of cure' can help avoid recurrence of cervical cancer and reduce the burden on healthcare systems.
Researchers from UC Irvine and Cal State Fullerton are partnering to conduct pilot research projects on cancer health disparities in Orange County. The alliance will focus on erasing disparities in cervical, stomach, and liver cancers, as well as increasing awareness of the risks among different ethnic groups.
A study found that survivors of cervical, blood, and colorectal cancers experience poorer physical and mental health-related quality of life compared to those with other types of cancer. The analysis estimated that 3.3 million and 1.4 million US cancer survivors face below-average physical and mental health, respectively.
A recent study found that nearly 38% of lesbians in the US had not been screened for cervical cancer according to recommended guidelines. Women who disclosed their sexual orientation to healthcare providers were more likely to undergo routine screening, highlighting the importance of effective communication between patients and providers.
A recent study found that nearly 4 out of 10 lesbians are not routinely screened for cervical cancer, highlighting the need for effective communication with healthcare providers. The study suggests that open communication between patients and providers can significantly increase screening rates among this population.
A study published in The Lancet found that cancer resulted in the loss of nearly 170 million years of healthy life worldwide in 2008. This significant burden was largely attributed to colorectal, lung, breast, and prostate cancers, with men in eastern Europe facing the largest cancer burden.
Researchers found that patient navigation services significantly decreased the time to diagnosis for female patients with abnormal breast or cervical cancer screening results. The study supports recent standard recommendations for all cancer care centers to provide patient navigation services.
Research finds that sexually abused women are less likely to get screened for cervical cancer, with 42% of those aged 25-49 screened within the previous 3 years. The procedure evokes traumatic memories and feelings of shame, leading some to avoid screening or experience anxiety.
The incidence of invasive cervical cancer has declined dramatically over the past several decades, thanks to increased use of Pap smears and prevention programs. However, disparities persist, particularly among underserved racial and ethnic minorities, rural areas, and low-income women.
A new report from the American Cancer Society reveals that cancer has surpassed heart disease as the leading cause of death among Hispanics in the US. The report highlights the unique factors contributing to this trend, including age distribution, socioeconomic status, and immigration history.
Researchers found a single HPV protein necessary for cervical cancer and pre-cancer growths to survive. A gene-silencing technique may cripple the protein and eliminate cervical cancer and pre-cancerous growths in mice, offering a potential new treatment option.
A $1.2 million grant will support a program providing HPV vaccine to hundreds of low-income women at UTMB's healthcare services, addressing barriers such as lack of awareness and limited access. The initiative aims to increase vaccination rates among Hispanic women at high risk for cervical cancer.
A comprehensive review of the recent medical literature evaluates the potential for reducing HPV-related illness burden by expanding routine vaccination to include young males. The authors present their recommendations on the cost-effectiveness of male HPV vaccination, which could lead to significant public health benefits.
A new study suggests that HIV-positive women with normal Pap tests and negative HPV tests can safely reduce cervical cancer screening frequency. The study found similar rates of cervical precancer and cancer in HIV-positive and HIV-negative women, paving the way for co-testing to reduce unnecessary screenings.
A recent study published in JAMA found that HIV-infected women with normal cervical cytology and negative oncogenic HPV DNA had a similar risk of cervical precancer and cancer to uninfected women over a 5-year period. The study's findings suggest that current screening guidelines may need to be revised for HIV-infected women.
A large national sample of women diagnosed with cervical cancer between 2000 and 2007 found that lack of insurance was the second strongest predictor of late-stage diagnosis, after age. The study suggests that screening should be made accessible and affordable for all women at higher risk of advanced-stage disease.
A study published in Pediatrics found that HPV vaccination significantly reduced infection rates among both vaccinated and unvaccinated young women. The vaccine's effectiveness was particularly notable among sexually experienced participants.
A new study has questioned the safety and feasibility of a controversial HPV vaccine trial in India, citing lack of data on cervical cancer incidence. Researchers found that figures for cervical cancer rates in India are low and do not justify the introduction of an HPV vaccination programme.
A population of cells in the squamo-columnar junction of the cervix have been found to be responsible for most HPV-associated cervical cancers. These cells can become cancerous when infected with HPV, while other cells in the cervix appear to be resistant to infection.
A team of researchers identified a unique set of cells at the squamocolumnar junction that express biomarkers found in all forms of invasive cervical cancers linked to HPV. These cells do not regenerate when excised, which has significant implications for diagnosis, prevention, and treatment of cervical cancer.
Researchers at Moffitt Cancer Center have developed a synthetic vaccine that induces tumor clearance in 100% of mice with HPV16-induced tumors. The vaccine, called TriVax-HPV, generates large numbers of cytotoxic T-cells targeting viral proteins, offering an alternative to conventional therapies for cervical cancer.
A study of 163 patients with cervical cancer found that 3D image-guided adaptive brachytherapy (IGABT) achieved high rates of tumor control and low side effects, making hysterectomies unnecessary for most women. The technique was effective in controlling the return and spread of the disease, and overall survival was 84% after three years.
New estimates suggest that around 16% of all cancers worldwide are infection-related, with a significant disparity between developed and developing countries. Infection-related cancers are largely preventable, particularly those associated with human papillomaviruses, Helicobacter pylori, hepatitis B and C viruses.
Researchers discover small molecule inhibitors that protect a tumor-suppressing protein targeted by viral proteins, killing infected cells. The inhibitors work by binding to the protein itself, allowing it to trigger normal cell division without disrupting the effect of HPV.
A new study published in The Lancet analyzed cancer death rates across India and found that oral, stomach, and lung cancers are major causes of death in men, while cervical, stomach, and breast cancers cause the most deaths among women. The study also highlighted significant geographical and social variations in cancer mortality rates.
The USPSTF recommends a three-year Pap smear schedule for women aged 21-65, allowing those over 30 to go five years between tests if they undergo HPV screening. Women under 21 and older than 65 are not recommended for routine screening.
A recent UNC study revealed pockets of high cervical cancer rates in North Carolina, highlighting the need for targeted education, vaccination, and screening programs. The study found that less affluent counties had higher rates and mortality rates were disproportionately high among African American women.
A recent study found that female cancer survivors have poorer health behaviors than women without a cancer history, including higher rates of smoking and weight gain. Researchers hope to capitalize on these 'teachable moments' to encourage healthier lifestyles among cancer survivors.
The study found that oral HPV infection was predominantly sexually transmitted and had peaks in different age ranges, with men having a significantly higher prevalence than women. Oral HPV prevalence was associated with several measures of sexual behavior, including the number of partners and current smoking habits.
A study found that HPV DNA testing of self-collected Pap specimens was more sensitive than visual inspection with acetic acid and liquid-based cytology, but less specific. This method could expand China's cervical cancer screening outreach without requiring medical professionals or facilities.
Researchers found that HIV induces expression of the COX-2/prostaglandin E2 inflammatory pathway in cervical tissue samples from Haitian women. Aspirin's potential role in preventing cervical cancer is being explored as a simple and inexpensive solution for high-risk populations.
The POBASCAM trial found HPV testing to be more sensitive and effective at detecting precancerous lesions, with fewer high-grade cervical lesions and cervical cancer in the second round of screening. HPV testing can lead to earlier detection and treatment of lesions, improving protection against cervical cancer.
A new study explores whether a polarized filter can enhance colposcopy, allowing doctors to detect early signs of cervical cancer more accurately. The approach has shown promise in reducing unnecessary biopsies and surgeries, particularly in young women where normal cell types can be difficult to distinguish.
A bivalent HPV vaccine has been shown to offer excellent protection against the most serious immediate precursor to invasive cervical cancer. The vaccine also partially protects against four other cancer-causing HPV types, which together with HPV16/18 cause about 85% of cervical cancer worldwide.
A new DIY screen for cervical cancer has been shown to be highly effective at detecting the disease in women who cannot access a traditional smear test. The test picked up over four times as many cases of cervical cancer and three times as many pre-cancerous conditions, with higher uptake among women compared to traditional screening.
Research suggests earlier male circumcision can reduce HIV and HPV transmission rates in South Africa. The study found that high prevalence of HPV among HIV-infected men and their female partners limits the effectiveness of male circumcision as a prevention method.
A study found that pediatricians in Appalachia are less likely to encourage parents to get the HPV vaccine for their children, citing a lack of information and cultural concerns. This is alarming as HPV infection is a major risk factor for cervical cancer, which disproportionately affects Appalachian women.
A researcher at Indiana University is investigating the most effective ways to present information about the HPV vaccine to young women, in an effort to boost vaccination rates. Her study will assess how women process and understand the information, as well as their attitudes and intentions toward vaccination.
Breast and cervical cancer cases are rising globally, with more women dying at younger ages in developing countries. The study reveals stark differences in trends between high- and low-income countries, highlighting the need for increased cancer screening and treatment programs in poor nations.
The study estimates 1.6 million new breast cancer cases and 425,000 new cervical cancer cases worldwide in 2010. Most cases occurred in developing countries, with a significant increase in women of reproductive age diagnosed with the diseases.
A large-scale study has found that intrauterine devices (IUDs) may protect against cervical cancer. The research involved over 20,000 women from different countries and revealed a significant reduction in cervical cancer risk among IUD users.
A new study suggests that Cervarix vaccine may be as effective in preventing cervical cancer with fewer than three doses, offering potential cost and logistics benefits. The researchers found similar protection levels among women receiving one, two, or three doses of the vaccine.
Researchers developed a typology to guide cost-effectiveness analysis of cervical cancer screening and vaccination strategies. They found that targeting racial subgroups with greater inequalities improved health outcomes, reduced cancer incidence, and was more effective and less costly than current methods.
A new study found that persistent HPV infections are associated with a higher risk of cervical cancer. The researchers suggest that re-testing every two years for HPV-positive women can provide useful guidance on the duration of infection and its risk.
A new study suggests that HPV testing for two high-risk strains (HPV16 and HPV18) detects more high-grade pre-cancerous lesions than current cervical cancer screening. The findings support the use of HPV testing as a primary screening tool to rule out disease, with cytology reserved for triage of women who test positive.
The bivalent HPV vaccine has been shown to protect against anal HPV 16 and 18 infections, preventing nearly 84% of cases in women without prior exposure. The vaccine also offers cross-protective efficacy against other cancer-causing HPV types, suggesting a broader potential for prevention of HPV-associated cancers.
A CDC study found that primary care providers continue to recommend annual cervical cancer screening, despite guidelines suggesting a less frequent screening interval. The study suggests that establishing a history of normal Pap tests is crucial in making guideline-supported screening interval recommendations.
A lack of understanding about HPV vaccination and its link to future cervical screening has been found among parents and girls in the UK. Despite being effective against two high-risk HPV types, vaccinated individuals still require regular cervical screenings to protect against other strains that can cause cancer.
The Cervical Cancer Prevention Program in Zambia has provided services to over 58,000 women, saving lives and establishing a new solution for routine prevention intervention in resource-constrained environments.
Researchers are developing an oral vaccine for cervical cancer and a combination prostate cancer vaccine, aiming to improve vaccination accessibility and affordability. The vaccines use nanoparticle-based Human Papillomavirus (HPV) formulations, potentially reducing costs and enabling mass vaccinations.
A new study found that radiologists using MRI can correctly identify the primary site of cancer in 79% of cases, even when biopsy results are inconclusive. This improves patient outcomes by providing more accurate treatment options.
Researchers discovered that lopinavir selectively kills HPV-infected non-cancerous cells while leaving healthy cells relatively unaffected. The study suggests a potential treatment for HPV-related cervical cancer using locally applied lopinavir cream or pessary.
A study of 435 women who underwent treatment for precancerous cervical lesions found that a three-cytological-smears post-treatment surveillance strategy is effective in identifying women at long-term risk of cervical cancer. By adding high-risk human papillomavirus (hrHPV) testing, the need for subsequent screens can be reduced.
Researchers at Tufts University School of Medicine have developed a protein-based inhibitor that blocks HPV protein expression in cell culture, paving the way for a topical treatment. The inhibitor, E2R, prevents viral gene transcription and has shown promise against various strains of HPV, including high-risk and low-risk types.
A study found that extending the HPV vaccine dosing schedule to every 3 months was comparable to the standard schedule in terms of antibody concentration levels. This alternative schedule may provide a more feasible option for expanding vaccine use in developing countries.
A study by Georgetown University Medical Center researchers suggests that activation of the beta-catenin oncogene is key to understanding why many women with HPV infection do not develop cervical cancer. The discovery could lead to new screening methods and therapeutic approaches, including targeting the Wnt pathway.
A recent study found that approximately 50% of men in the general population are infected with human papillomavirus (HPV), a virus known for causing cervical cancer in women. The study also revealed high incidence and transmission rates, particularly among men with multiple partners.
A new study led by UCSF found that the HPV vaccine can prevent 90 percent of genital warts in men when offered before exposure to the four HPV strains covered by the vaccine. The vaccine also showed a nearly 66 percent effectiveness rate in the general population of young men, regardless of prior exposure.
A study by St. Michael's Hospital found that only one in five South Asian immigrants over 50 had a recent Pap test, compared to 79% of Canadian-born women with high-income neighborhoods and primary care doctors. The low screening rates may be due to cultural factors and lack of awareness about the importance of the test.